NCT00139750 - 12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation | Biotech Hunter

Enrollment

600

Participants

Timeline

Start Date

December 31, 2004

Study Completion Date

February 28, 2006

Conditions

Smoking Cessation

Interventions

DRUG

CP-526,555 (varenicline)

Trial Locations (15)

Pfizer Investigational Site, Noda

Pfizer Investigational Site, Fukuoka

Pfizer Investigational Site, Sapporo

Pfizer Investigational Site, Yokohama

Pfizer Investigational Site, Ohita

Pfizer Investigational Site, Beppu-shi

Pfizer Investigational Site, Toyonaka

Pfizer Investigational Site, Tosu

Pfizer Investigational Site, Hamamatsu

Pfizer Investigational Site, Edogawa-ku

Pfizer Investigational Site, Minato-ku

Pfizer Investigational Site, Musashino

Pfizer Investigational Site, Setagaya-ku

Pfizer Investigational Site, Shinagawa-ku

Pfizer Investigational Site, Toshima-ku